This website is intended for healthcare professionals only.
NEW REAL WORLD EVIDENCE IN 3rd LINE mCRC
Prof Eric Van Cutsem
Professor and Division Head of Digestive Oncology, University of Leuven (KUL) and University Hospitals Gasthuisberg, Leuven, Belgium
Dr Shouki Bazarbashi
Head, Section of Medical Oncology, King Faisal Specialist Hospital & Research Centre
This webinar focuses on real-world evidence and mCRC patients selection. The choice of 3L treatment should depend on performance status as well as several patient characteristics. Hence, treatment sequence and the choice of 3L treatment could open new possibility for 4L treatment. An interactive clinical patient discusses the 3L choices and subsequent 4L treatment options.
Key points covered
This webinar highlights the importance of treatment algorithm to improve the outcomes of patients with mCR, through real-world evidence.
An interactive clinical patient case was presented to discuss 3L and 4L treatments.
This webinar presented FTD/TPI and regorafenib's main RWE data in mCRC patients, worldwide.
Webinar Replay
Featured Speakers
Prof. Eric Van Cutsem
Eric Van Cutsem, MD, PhD, is full professor and Division Head of Digestive Oncology at University of Leuven and University Hospitals Gasthuisberg, Leuven, Belgium and has several functions at the Leuven Cancer Institute. He co-founded ESMO GI/World Congress on Gastrointestinal Cancer, and is Chair of the meeting in Barcelona, Spain. He is also member of many international societies and is member of the governmental commission of recognition for specialists in gastroenterology/digestive oncology. His research focuses on the development of new treatment strategies for various Gastrointestinal cancers, including drug development and identification of molecular markers and diagnostic tools.
Dr. Shouki Bazarbashi
Dr. Shouki Bazarbashi, MBBS, MD currently serves as head of the section of medical oncology at King Faisal Specialist Hospital & Research Centre and is also Chair of the research ethics committee. He has published extensively in GI and GU cancer aswell as clinical guidelines, more than 125 abstractsand over 90 publications in peer-reviewed journals. He is also a member of the scientific committees of the Saudi Cancer Registry and served on the scientific
